Will Hims & Hers Fall Along With Novo Nordisk?
One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. NYSE: HIMS, not only due to its rampant price action over the past six months, but also because of its underlying growth story, which almost makes it feel like a miracle in the making. The reason behind its popularity lies in the fact that it combines the safety of health services along with the sort of growth reserved for the technology space of the market.
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Outperforms Broader Market: What You Need to Know
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $58.68, indicating a +1.79% shift from the previous trading day.
HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?
Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.
Hims & Hers Health, Inc. (HIMS) Reports Next Week: Wall Street Expects Earnings Growth
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health: What's Wall Street Missing In This Weight-Loss Stock?
Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million users fueling growth. Despite the Novo Nordisk partnership loss, Hims quickly pivoted, expanding its weight-loss offerings and deepening its holistic digital health platform. Recent financials remained robust with Q1 sales up 111% YOY, recurring revenues, strong cash flow, and rising ARPU, supporting a path to sustained profitability.
Is Hims & Hers the Newest Meme Stock Darling?
Key Points in This Article: Hims & Hers (HIMS) telehealth platform drives strong growth, but the Novo Nordisk partnership fallout and regulatory risks pose challenges.
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.
How Hims & Hers Health Is Quietly Changing Healthcare
Hims surpassed 2.4 million subscribers with 95% recurring revenue and over 85% retention, driving 111% YoY revenue growth. Average monthly revenue per subscriber rose 50% YoY, showing strong monetization through personalization, bundling, and chronic care expansion. Despite Novo deal fallout, Hims continues scaling GLP-1 offerings and accelerating proprietary semaglutide development amid regulatory scrutiny.
